Market Overview

JP Morgan Initiates Bioline RX With Market Outperform


JP Morgan initiated coverage on Bioline RX Ltd (NASDAQ: BLRX) with a Market Outperform rating.

The target price for Bioline RX is set to $5.

Bioline RX shares have dropped 4.17 percent over the past 52 weeks, while the S&P 500 index has gained 7.51 percent in the same period.

Bioline RX shares gained 4.34 percent to $2.16 in pre-market trading.

Latest Ratings for BLRX

Aug 2017Initiates Coverage OnOutperform
May 2017UpgradesHoldBuy
Feb 2017Initiates Coverage OnBuy

View More Analyst Ratings for BLRX
View the Latest Analyst Ratings

Posted-In: JP MorganInitiation Analyst Ratings


Related Articles (BLRX)

View Comments and Join the Discussion!

Latest Ratings

TIGOBank of AmericaMaintains76.0
NVDABank of AmericaMaintains250.0
ZENRBC CapitalMaintains100.0
ZMorgan StanleyMaintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Evercore ISI Initiates E. W. Scripps At Hold

JP Morgan Initiates Communications Sales & Leasing At Overweight